The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Antibody Drug Conjugates Market (5th Edition), 2019-2030

  • Lowest Price Guaranteed From USD 4,499

  • Published
    August 2019

  • Pages
    615

  • View Count
    8969

Example Insights

conjugated antibody companies Context conjugated antibody companies Developers conjugated antibody companies Development Pipeline
conjugated antibody companies Market Overview conjugated antibody companies Key Biological Targets conjugated antibody companies Key Opinion Leaders
conjugated antibody companies Patent Analysis conjugated antibody companies Funding and Investments conjugated antibody companies Partnerships and Collaborations
conjugated antibody companies Combination Therapies conjugated antibody companies Commercialization Strategies conjugated antibody companies CMOs
conjugated antibody companies Promotional Strategies conjugated antibody companies Forecast conjugated antibody companies Market Forecast

 

Overview

We are aware that various second and third generation ADCs that are being developed by different companies, have shown significant improvements, in terms of clinical results, compared to traditional ADCs. As a result, novel ADC technologies have garnered the attention of physicians, patients and their families, having demonstrated improved clinical outcomes. We are optimistic about the growth of the ADCs market and believe that competition in this domain is likely to increase in the future.

- Executive Director / Chief Innovation Officer, a big pharma company

With six approved and marketed drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), antibody drug conjugates (ADCs) have become recognized as a potent class of targeted therapeutic agents catering to oncology and hematological diseases markets. The success of such conjugated products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, while limiting off target toxicities. Presently, ADCs are considered a part of mainstream healthcare regimens, having generated significant enthusiasm within the medical science community across the world. 

The growing popularity and therapeutic potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed / granted; the cumulative patent count has increased from 1,395 in 2009 to over 16,500 in the first half of 2019. With more than 200 ADCs in clinical / preclinical stages of development, the industry is gradually shifting from relying on conventional technologies to newer and more robust approaches to conjugate such complex biomolecules. Over the years, a number of well-funded start-ups / small companies, offering novel conjugation technologies, more potent warheads and advanced linker technologies, have been established. In fact, multiple licensing agreements / collaborations have been inked in the past few years between drug developers and technology providers to advance the development of pipeline ADC candidates.  

Using ADCs in combination with other drug / therapy classes is an emerging concept and multiple companies are evaluating their proprietary ADC candidates in combination with other established therapeutic classes, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies. In addition, several other companies have introduced certain novel types of conjugated drug molecules; example of such companies include Bicycle Therapeutics (bicycle drug conjugate), BlinkBio (tunable drug conjugates), Cellectar Biosciences (phospholipid drug conjugate), Centrose (extracellular drug conjugate), Esperance Pharmaceuticals (peptide conjugate) and Nordic Nanovector (radionucleotide conjugate). We expect the ADC therapeutics market to growth at a healthy rate in the mid to long-term, driven by the introduction of new combination therapies involving ADCs, innovative ADC development and conjugation technologies, applications beyond oncology and the expansion of existing marketing authorizations to newer geographies across the world.

Scope of the Report

The ‘Antibody Drug Conjugates Market (5th Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency.
  • Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios; each profile features an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook.
  • An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
  • A list of key opinion leaders (KOLs) within this domain, featuring detailed 2X2 matrices to assess the relative experience of key individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations and strength of professional network (based on information available on LinkedIn).
  • An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials. 
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant agreements. 
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing ADCs.
  • An in-depth analysis of the various patents that have been filed / granted related to ADCs till May 2019. It includes information on key parameters, such as patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April), highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions and leading recipient organizations.
  • An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products. 
  • An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and ADCETRIS®.
  • An assessment of the various therapeutics that are being evaluated in combination with ADCs. The study also presents the likely evolution of these therapeutics across different indications. 
  • A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations; in addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. It also includes an analysis of the different methods used in estimating FIH doses. In addition, it highlights the possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD).
  • An elaborate discussion on various factors that form the basis for the pricing of ADC products, featuring different models / approaches that pharmaceutical companies may choose to adopt while deciding the price of their respective lead therapy candidates that are likely to be marketed in the coming years.
  • A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
  • A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving ADCs, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for ADCs, over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. The report includes potential sales forecasts of ADCs that are currently marketed or are in late stages of development. Additionally, it provides forecasts of the overall ADCs market, wherein the current and upcoming opportunity is segmented across [A] type of payload (MMAE, DM4, camptothecin, DM1, MMAF and others), [B] type of linker (VC, Sulfo-SPDB, SMCC, VA, hydrazone linker and others), [C] target indications (breast cancer, lymphoma (HL, NHL, ALCL), leukemia (AML, ALL), urothelial cancer, lung cancer (NSCLC, SCLC), ovarian cancer and others), [D] target antigens (CD30, HER2, CD22, CD33 and others (HER4, TROP-2, EGFR, FOLR1, MSLN, CD142, CD79b, DLL3, CD37, Nectin – 4, LIV-1, c-MET, BCMA, CD25, CD19 and ENPP3)), [E] technology providers (Seattle Genetics, ImmunoGen, StemCentRx, Immunomedics and others), and [F] key geographies (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapeutics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Alan Burnett (Professor, School of Medicine, Cardiff University)
  • Aldo Braca (President and Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
  • John Burt (Chief Executive Officer, Abzena)
  • Jennifer L. Mitcham (Director,  SMARTag ADCs and Bioconjugates, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Healthcare)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
  • Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai)
  • Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
  • Anonymous (Director, Business Development, Leading CMO)
  • Anonymous (Chief Executive Officer, Leading CMO)


All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the ADC market in the short to mid-term and long term.

Chapter 3 provides a general introduction to ADCs. In this section, we have discussed, in detail, the concept of ADC, its various components, mechanisms of action and advantages over traditional targeted therapies. The chapter also presents a brief description of the absorption, distribution, metabolism and excretion (ADME) properties of the various ADCs that are under development.

Chapter 4 provides a comprehensive overview of the market landscape of ADCs that are either approved or under development. This chapter includes information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency. The chapter also highlights the various ADCs that have been discontinued over the last few years.

Chapter 5 presents elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios; each profile features an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook.

Chapter 6 identifies the most commonly targeted therapeutic indications and features brief descriptions of the ADC candidates being developed against them. It highlights the key epidemiological facts about the diseases and currently available treatment options, other than ADCs.

Chapter 7 provides an analysis of KOLs in the field of ADCs. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with the information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The credibility and (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on number of publications, number of citations, number of clinical trials, number of affiliations and extent of professional network.

Chapter 8 presents an insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved drug development efforts based on a singular target and geographical distribution of associated clinical trials.

Chapter 9 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked between the players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of year of an agreement / partnership, the type of partnership model (R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and others, companies involved, and regional distribution of the collaborations.

Chapter 10 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till July 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 11 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to ADCs. For this analysis, we looked at the patents that have been published by various players, till May 2019. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 12 provides information on the various grants that were awarded to research institutes conducting projects related to ADCs, between 2011 and 2019 (till April). The analysis also highlights important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions and leading recipient organizations.

Chapter 13 presents an elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch and during / post launch. It also highlights an in-depth analysis and timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products. In addition, it provides a general overview of the drugs considered for studying the strategies in detail.

Chapter 14 highlights the key promotional strategies that are being implemented by the developers of marketed products, including POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and ADCETRIS®. The promotional aspects covered in the chapter include details provided on the product website (including key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 15 features an overview of the various therapeutics being evaluated in combination with ADCs. It also features a study of the likely evolution of these therapeutics across different therapeutic indications.

Chapter 16 provides a review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations. In addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.

Chapter 17 provides an overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection. The chapter presents insights from recently conducted studies in different animal models, analyzing the different methods used in estimating FIH doses. In addition, it highlights possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD). The chapter highlights different types of ADC related toxicities observed in animal models, highlighting the doses at which these toxicities were observed.

Chapter 18 highlights our views on the various factors that must be taken into consideration while deciding the prices of ADC products. It features discussions on different models / approaches that pharmaceutical companies may choose to adopt while deciding the prices at which their ADC products can be marketed. 

Chapter 19 provides details of the players that offer contract manufacturing services for ADCs, or possess the necessary capabilities and infrastructure to manufacture such products in-house. The chapter illustrates the manufacturing capabilities of different contract manufacturers highlighting their expansion plans and other agreements inked between companies.

Chapter 20 is a case study focused on the use of companion diagnostics in the field of ADCs. It provides a list of companies offering companion diagnostics for targets being targeted by ADCs, including information on their geographical location, affiliated biomarker, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidate(s) for which it is already available.

Chapter 21 features an elaborate discussion on the future commercial opportunity for the ADCs. It provides a comprehensive market forecast analysis of the molecules that are approved or are in late stages of clinical development taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely prices of the therapeutics. The chapter also presents a detailed market segmentation on the basis of [A] type of payload (MMAE, DM4, camptothecin, DM1, MMAF and others), [B] type of linker (VC, Sulfo-SPDB, SMCC, VA, hydrazone linker and others), [C] target indications (breast cancer, lymphoma (HL, NHL, ALCL), leukemia (AML, ALL), urothelial cancer, lung cancer (NSCLC, SCLC), ovarian cancer and others, [D] target antigens (CD30, HER2, CD22, CD33 and others (HER4, TROP-2, EGFR, FOLR1, MSLN, CD142, CD79b, DLL3, CD37, Nectin – 4, LIV-1, c-MET, BCMA, CD25, CD19 and ENPP3,)) [E] technology providers (Seattle Genetics, ImmunoGen, StemCentRx, Immunomedics and others), and [F] key geographies (North America, Europe and Asia Pacific).

Chapter 22 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the ADCs market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 23 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 24 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Alan Burnett (Professor, School of Medicine, Cardiff University),     Aldo Braca (President and Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix),     Christian Bailly (Director of CDMO, Pierre Fabre), Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), John Burt (Chief Executive Officer, Abzena), Jennifer L. Mitcham (Director,  SMARTag ADCs and Bioconjugates, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services), Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai), and Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics).

Chapter 25 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 26 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Anticancer Therapy
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
 
3.4. Monoclonal Antibody-Based Anticancer Therapies
3.5. Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
 
3.6. Advantages of ADC Therapeutics over Traditional Therapeutic Interventions
3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Excretion
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. ADC Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Linker
4.2.10. Analysis by Type of Payload / Warhead
4.2.11. Key Technology Providers
4.2.12. Discontinued Drugs
 
4.3. ADC Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Indication
4.3.3. Analysis by Target Antigen
4.3.4. Key Players: Analysis by Number of ADC Therapeutics
 
4.4. ADC Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Geographical Location
4.4.4. Logo Landscape: Analysis by Size and Target Indication
4.5. Novel Drug Conjugates
 
5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. AbbVie
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview
5.2.3.1. Rovalpituzumab Tesirine / ROVA-T
5.2.3.1.1 Drug Overview
5.2.3.1.2. Mechanism of Action
5.2.3.1.3. Clinical Development Status
5.2.3.1.4. Key Clinical Trial Results
 
5.2.3.2. Teliso-V / Telisotuzumab Vedotin / ABBV-399
5.2.3.2.1 Drug Overview
5.2.3.2.2. Mechanism of Action
5.2.3.2.3. Clinical Development Status
5.2.3.2.4. Key Clinical Trial Results
5.2.4. Recent Developments and Future Outlook
 
5.3. Astellas Pharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview
5.3.3.1. Enfortumab Vedotin
5.3.3.1.1. Drug Overview
5.3.3.1.2. Mechanism of Action
5.3.3.1.3. Clinical Development Status
5.3.3.1.4. Key Clinical Trial Results
 
5.3.3.2. ASG16-M8F
5.3.3.2.1. Drug Overview
5.3.3.2.2. Mechanism of Action
5.3.3.2.3. Clinical Development Status
5.3.3.2.4. Key Clinical Trial Results
5.3.4. Recent Developments and Future Outlook
5.4. AstraZeneca
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. LUMOXITI™
5.4.3.1.1. Drug Overview
5.4.3.1.2. Mechanism of Action
5.4.3.1.3. Clinical Development Status
5.4.3.1.4. Key Clinical Trial Results
5.4.4. Recent Developments and Future Outlook
 
5.5. Daiichi Sankyo
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview
5.5.3.1. Trastuzumab deruxtecan / DS-8201a / DS 8201
5.5.3.1.1. Drug Overview
5.5.3.1.2. Mechanism of Action
5.5.3.1.3. Clinical Development Status
5.5.3.1.4. Key Clinical Trial Results
5.5.4. Recent Developments and Future Outlook
 
5.6. ImmunoGen
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.3.1. IMGN853 / Mirvetuximab soravtansine
5.6.3.1.1. Drug Overview
5.6.3.1.2. Mechanism of Action
5.6.3.1.3. Clinical Development Status
5.6.3.1.4. Key Clinical Trial Results
5.6.4. Recent Developments and Future Outlook
5.7. Immunomedics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview
5.7.3.1. IMMU-130
5.7.3.1.1. Drug Overview
5.7.3.1.2. Mechanism of Action
5.7.3.1.3. Clinical Development Status
5.7.3.1.4. Key Clinical Trial Results
5.7.4. Recent Developments and Future Outlook
 
5.8. Pfizer
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview
5.8.3.1. CMC-544 / BESPONSA® / Inotuzumab Ozogamicin
5.8.3.1.1. Drug Overview
5.8.3.1.2. Mechanism of Action
5.8.3.1.3. Clinical Development Status
5.8.3.1.4. Key Clinical Trial Results
 
5.8.3.2. MYLOTARG™ / Gemtuzumab Ozogamicin
5.8.3.2.1. Drug Overview
5.8.3.2.2. Mechanism of Action
5.8.3.2.3. Clinical Development Status
5.8.3.2.4. Key Clinical Trial Results
5.8.4. Recent Developments and Future Outlook
 
5.9. Roche / Genentech
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Pipeline Overview
5.9.3.1. KADCYLA®
5.9.3.1.1. Drug Overview
5.9.3.1.2. Mechanism of Action
5.9.3.1.3. Clinical Development Status
5.9.3.1.4. Key Clinical Trial Results
 
5.9.3.2. RG-7596
5.9.3.2.1. Drug Overview
5.9.3.2.2. Mechanism of Action
5.9.3.2.3. Clinical Development Status
5.9.3.2.4. Key Clinical Trial Results
5.9.4. Recent Developments and Future Outlook
 
5.10. Seattle Genetics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Pipeline Overview
5.10.3.1. ADCETRIS®
5.10.3.1.1. Drug Overview
5.10.3.1.2. Mechanism of Action
5.10.3.1.3. Clinical Development Status
5.10.3.1.4. Key Clinical Trial Results
 
5.10.3.2. SGN- LIV1A
5.10.3.2.1. Drug Overview
5.10.3.2.2. Mechanism of Action
5.10.3.2.3. Clinical Development Status
5.10.3.2.4. Key Clinical Trial Results
5.10.4. Recent Developments and Future Outlook
 
5.11. Synthon
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Pipeline Overview
5.11.3.1. SYD985 / Trastuzumab Duocarmazine
5.11.3.1.1. Drug Overview
5.11.3.1.2. Mechanism of Action
5.11.3.1.3. Clinical Development Status
5.11.3.1.4. Key Clinical Trial Results
5.11.4. Recent Developments and Future Outlook
 
5.12. Other Companies
5.12.1. Bayer HealthCare
5.12.1.1. Company Overview
5.12.1.2. Financial Information
5.12.1.3. Pipeline Overview
5.12.1.4. Recent Developments and Future Outlook
 
5.12.2. Biotest Pharmaceuticals
5.12.2.1. Company Overview
5.12.2.2. Financial Information
5.12.2.3. Pipeline Overview
5.12.2.4. Recent Developments and Future Outlook
 
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction and Epidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia
6.2.1.2. Lymphoma: Introduction and Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.4. ADC Therapeutics for Leukemia / Lymphoma
 
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADC Therapeutics for Multiple Myeloma
 
6.3. Solid Tumors
6.3.1. Lung Cancer
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADC Therapeutics for Lung Cancer
 
6.3.2. Breast Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADC Therapeutics for Breast Cancer
 
6.3.3. Ovarian Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADC Therapeutics for Ovarian Cancer
 
6.3.4. Bladder Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADC Therapeutics for Bladder Cancer
 
6.3.5. Colorectal Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADC Therapeutics for Colorectal Cancer
 
6.3.6. Prostate Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADC Therapeutics for Prostate Cancer
 
6.3.7. Gastric Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADC Therapeutics for Prostate Cancer
 
7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Methodology
 
7.3. Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials
7.3.1. Geographical Distribution of Key Opinion Leaders
7.3.1.1. Experts on ADCETRIS®
7.3.1.2. Experts on KADCYLA®
7.3.1.3. Experts on MYLOTARG™
7.3.1.4. Experts on Other ADCs
 
7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
 
7.6. Most Active Key Opinion Leaders
7.6.1. Profile: KOL A (Celgene)
7.6.2. Profile: KOL B (Western Regional Medical Center)
7.6.3. Profile: KOL C (MedStar Washington Hospital Center)
7.6.4. Profile: KOL D (Cancer Institute and Hospital)
7.6.5. Profile: KOL E (Comprehensive Cancer Centers of Nevada)
7.6.6. Profile: KOL F (Hopital Tenon)
7.6.7. Profile: KOL G (Cleveland Clinic)
 
8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Competitiveness Analysis: Key Clinical Targets for ADCs
8.3.1. Four-Dimensional Bubble Analysis
8.3.2 Five-Dimensional Spider Web Analysis
 
8.4. Competitiveness Analysis: Key Preclinical Targets for ADCs
8.4.1. Two-Dimensional Scatter Plot Analysis
 
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. ADC Therapeutics: List of Partnerships and Collaborations
9.3.1 Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnerships
9.3.3. Most Active Players: Analysis by Number of Partnerships
 
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements
 
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. ADC Therapeutics: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. High Value Deals: Analysis by Year
10.3.4. Analysis by Type of Funding
 
10.3.5. Most Active Players
10.3.5.1. Analysis by Number of Funding Instances
10.3.5.2. Analysis by Amount Invested
10.4. Concluding Remarks
 
11. PATENT ANALYSIS
11 Patent Analysis
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. ADC Therapeutics: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Geographical Location
11.3.3. Analysis by CPC Classification
11.3.4. Emerging Focus Areas
11.3.5. Analysis by Type of Industry
11.3.6. Leading Players: Analysis by Number of Patents
11.4. ADC Therapeutics: Patent Benchmarking Analysis (Industry Players)
11.4.1. Analysis by Patent Characteristics
11.4.2. Analysis By Geographical Location
11.5. ADC Therapeutics: Patent Valuation Analysis
 
12. ACADEMIC GRANTS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: List of Academic Grants
12.3.1. Analysis by Number of Grants
12.3.2. Analysis by Type of Grant
12.3.3. Analysis by Grant Amount
12.3.4. Analysis by Focus Area
12.3.5. Analysis by Support Period
 
12.4. Leading Organizations: Analysis by Number of Grants
12.5. Analysis by Type of Recipient Organization
12.6. Analysis by Administering Institute Center
12.7. Analysis by Funding Institute Center
12.8. Key Project Leaders: Analysis By Number of Grants
 
13. KEY COMMMERCIALIZATION STRATEGIES
13.1. Chapter Overview
13.2. Successful Drug Launch Strategy: ROOTS Framework
13.3. Successful Drug Launch Strategy: Product Differentiation
13.4. Common Commercialization Strategies Adopted Based on Development Stage of Product
 
13.5. Approved Molecules For ADCs
13.5.1. ADCETRIS®
13.5.2. KADCYLA®
13.5.3. MYLOTARG™
13.5.4. BESPONSA®
13.5.5. LUMOXITI™
13.5.5. POLIVY™
 
13.6. Key Commercialization Strategies Adopted by Companies Developing ADCs
13.6.1. Strategies Adopted Before Drug Approval
13.6.1.2. Collaboration with Internal Stakeholders and Pharmaceutical Firms
 
13.6.2. Strategies Adopted During / Post Drug Approval
13.6.2.1. Geographical Expansion
13.6.2.2. Participation in Global Events
13.6.2.3. Awareness Through Product Websites
13.6.2.4. Collaboration with Internal Stakeholders and Pharmaceutical Firms
13.7. Concluding Remarks
 
14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Brochure and Informative Downloads
 
14.5. ADCETRIS®: Promotional Analysis
14.5.1. Product Website Analysis
14.5.1.1. Messages for Healthcare Professionals
14.5.1.2. Messages For Patients
14.5.2. Patient Support Services and Informative Downloads
14.5.3. Other Promotional Activities
14.5.3.1. Presence in Conferences
 
14.6. KADCYLA®: Promotional Analysis
14.6.1. Product Website Analysis
14.6.1.1. Messages for Healthcare Professionals
14.6.1.2. Messages for Patients
14.6.2. Patient Support Services and Informative Downloads
14.6.3. Other Promotional Activities
14.6.3.1. Presence in Conferences
 
14.7. MYLOTARG™: Promotional Analysis
14.7.1. Product Website Analysis
14.7.1.1. Messages for Healthcare Professionals
14.7.1.2. Messages for Patients
14.7.2. Patient Support Services and Informative Downloads
14.7.3. Other Promotional Activities
14.7.3.1. Presence in Conferences
 
14.8. BESPONSA®: Promotional Analysis
14.8.1. Product Website Analysis
14.8.1.1. Messages for Healthcare Professionals
14.8.1.2. Messages for Patients
14.8.2. Patient Support Services and Informative Downloads
14.8.3. Other Promotional Activities
14.8.3.1. Presence in Conferences
 
14.9. LUMOXITI™: Promotional Analysis
14.9.1. Product Website Analysis
14.9.1.1. Messages for Healthcare Professionals
14.9.1.2. Messages for Patients
14.9.2. Patient Support Services and Informative Downloads
14.9.3. Other Promotional Activities
14.9.3.1. Presence in Conferences
 
14.10. POLIVY™: Promotional Analysis
14.10.1. Product Website Analysis
14.10.1.1. Messages for Healthcare Professionals
14.10.1.2. Messages for Patients
14.10.2. Patient Support Services and Informative Downloads
14.10.3. Other Promotional Activities
14.10.3.1. Presence in Conferences
 
15. COMBINATION THERAPIES
15.1. Chapter Overview
15.2. Combination Therapy: History of Development
15.3. FDA-approved Combination Therapies in Oncology
 
15.4. Combination Therapy: FDA Guidelines
15.4.1. Combinations of Marketed Drugs
15.4.2. Combinations of Marketed Drugs with New Molecular Entities
15.4.3. Combinations of New Molecular Entities
 
15.5. Combination Therapies: ADCs
15.5.1. Completed / Ongoing Clinical Studies of ADCs
15.5.1.1. Analysis by Type of Therapy
15.5.2. Completed / Ongoing Clinical Studies of ADC-based Combination Therapies
15.5.2.1. Analysis by Highest Phase of Development
15.5.2.2. Analysis by Current Trial Status
15.5.2.3. Analysis by Type of Combination
15.5.2.4. Analysis by Indication and Type of Combination
 
16. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
16.1. Chapter Overview
16.2. First Generation ADC Technologies
 
16.3. Second Generation ADC Technologies
16.3.1. Cysteine and Selenocysteine Engineering
16.3.2. Unnatural Amino Acid Engineering
16.3.3. Amino-Terminal Engineered Serine
 
16.4. Third Generation ADC Technologies
16.4.1. Enzyme-Assisted Ligation Approaches
16.4.2. Glycan Remodeling Approaches
16.4.3. Ligation at Fab Nucleotide-Binding Site
16.4.4. Cysteine Rebridging
16.4.5. Preventing / Limiting Retro-Michael Drug Deconjugation
16.5. Evolutionary Analysis of Conjugation Technologies
 
17. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
17.1. Chapter Overview
17.2. ADCs and Non-Clinical Studies
17.3. ICH S9 Guidelines
 
17.4. Investigational New Drug (IND)-Enabling Study Designs
17.4.1. Example Case: KADCYLA®
 
17.5. Toxicities in Animal Models
17.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
17.7. Other Key Considerations for Study Design
 
18. COST PRICE ANALYSIS
18.1. Chapter Overview
18.2. Factors Contributing Towards the High Price of ADC Therapeutics
18.3. ADC Therapeutics Market: Pricing Models
18.3.1. On the Basis of Associated Costs
18.3.2. On the Basis of Competition
18.3.3. On the Basis of Patient Segment
18.4. Reimbursement Considerations for ADC Therapeutics
 
19. CASE STUDY: CONTRACT MANUFACTURING OF ADC
19.1. Chapter Overview
19.2. Key Steps for ADC Manufacturing
19.3. Technical Concerns Related to ADC Manufacturing
19.4. Challenges Associated with Supply Chain and Method Transfer
19.5. Limitations of In-House Manufacturing
19.6. Investments in ADC Manufacturing Capability Expansions
19.7. Collaborations Established for ADC Manufacturing
19.8. Growing Demand for Contract Manufacturing
19.9. Emergence of Start-Ups Offering Contract Services
19.10. CMOs with Linker Manufacturing Capabilities
19.11. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
19.12. CMOs with Conjugation Capabilities
19.13. ADC One Stop Shops
 
20. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS
20.1. Chapter Overview
20.1.1. Advantages of Companion Diagnostics
20.1.2. Disadvantages of Companion Diagnostics
 
20.2. Companion Diagnostics for ADC Therapeutics
20.3. ADC Therapeutics: List of Companion Diagnostics
20.3.1. Analysis by Type of Target
20.3.2. Analysis by Type of Cancer Indication
20.4. Concluding Remarks
 
21. MARKET FORECAST AND OPPORTUNITY ANALYSIS
21.1. Chapter Overview
21.2. Scope and Limitations
21.3. Forecast Methodology
 
21.4. Overall ADC Therapeutics Market
21.4.1. ADC Therapeutics Market: Distribution by Target Indication
21.4.2. ADC Therapeutics Market: Distribution by Type of Linker
21.4.3. ADC Therapeutics Market: Distribution by Type of Payload
21.4.4. ADC Therapeutics Market: Distribution by Target Antigen
21.4.5. ADC Therapeutics Market: Distribution by Geography
21.4.6. ADC Therapeutics Market: Distribution by Technology Providers
 
21.5. ADC Therapeutics Market: Individual Drug Sales Forecasts
21.5.1. ADCETRIS® / Brentuximab Vedotin
21.5.1.1. Target Patient Population
21.5.1.2. Sales Forecast
 
21.5.2. KADCYLA® / Ado-trastuzumab Emtansine
21.5.2.1. Target Patient Population
21.5.2.2. Sales Forecast
 
21.5.3. MYLOTARG™ / Gemtuzumab Ozogamicin
21.5.3.1. Target Patient Population
21.5.3.2. Sales Forecast
 
21.5.4. BESPONSA® / Inotuzumab Ozogamicin
21.5.4.1. Target Patient Population
21.5.4.2. Sales Forecast
 
21.5.5. LUMOXITI™
21.5.5.1. Target Patient Population
21.5.5.2. Sales Forecast
 
21.5.6. POLIVYTM / Polatuzumab vedotin-piiq / RG7596
21.5.6.1. Target Patient Population
21.5.6.2. Sales Forecast
 
21.5.7. ASG-22ME / Enfortumab Vedotin
21.5.7.1. Target Patient Population
21.5.7.2. Sales Forecast
 
21.5.8. BAT8001
21.5.8.1. Target Patient Population
21.5.8.2. Sales Forecast
 
21.5.9. DS-8201a / DS 8201 / Trastuzumab Deruxtecan
21.5.9.1. Target Patient Population
21.5.9.2. Sales Forecast
 
21.5.10. IMMU-132 / Sacituzumab Govitecan
21.5.10.1. Target Patient Population
21.5.10.2. Sales Forecast
 
21.5.11. IMGN853 / Mirvetuximab Soravtansine
21.5.11.1. Target Patient Population
21.5.11.2. Sales Forecast
 
21.5.12. lpituzumab TesirineRova-T / Rova
21.5.12.1. Target Patient Population
21.5.12.2. Sales Forecast
 
21.5.13. SYD985 / Trastuzumab Duocarmazine
21.5.13.1. Target Patient Population
21.5.13.2. Sales Forecast
 
21.5.14. ABBV-399 / Teliso-V / Telisotuzumab Vedotin
21.5.14.1. Target Patient Population
21.5.14.2. Sales Forecast
 
21.5.15. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine
21.5.15.1. Target Patient Population
21.5.15.2. Sales Forecast
 
21.5.16. ADCT-402 / Loncastuximab Tesirine
21.5.16.1. Target Patient Population
21.5.16.2. Sales Forecast
 
21.5.17. AGS 16M8F / AGS 16C3F
21.5.17.1. Target Patient Population
21.5.17.2. Sales Forecast
 
21.5.18. AVID100
21.5.18.1. Target Patient Population
21.5.18.2. Sales Forecast
 
21.5.19. BAY 94-9343
21.5.19.1. Target Patient Population
21.5.19.2. Sales Forecast
 
21.5.20. GSK 2857916 / Anti-BCMA ADC
21.5.20.1. Target Patient Population
21.5.20.2. Sales Forecast
 
21.5.21. HuMax-TF-ADC / Tisotumab Vedotin
21.5.21.1. Target Patient Population
21.5.21.2. Sales Forecast
 
21.5.22. IMGN529 / Debio 1562 / Naratuximab Emtansine
21.5.22.1. Target Patient Population
21.5.22.2. Sales Forecast
 
21.5.23. IMMU-130 / Sacituzumab Govitecan
21.5.23.1. Target Patient Population
21.5.23.2. Sales Forecast
 
21.5.24. RC48
21.5.24.1. Target Patient Population
21.5.24.2. Sales Forecast
 
21.5.25. SGN-LIV1A / Ladiratuzumab Vedotin
21.5.25.1. Target Patient Population
21.5.25.2. Sales Forecast
 
22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Concluding Remarks
 
23. CONCLUSION
23.1. Chapter Overview
23.2. Key Takeaways
 
24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Abzena
24.2.1. Company Snapshot
24.2.2. Interview Transcript: John Burt, Chief Executive Officer
 
24.3. Ajinomoto Bio-Pharma Services
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager
 
24.4. BSP Pharmaceuticals
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
 
24.5. Catalent Pharma Solutions
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Jennifer L. Mitcham, Director, SMARTag ADCs and Bioconjugates, and Stacy McDonald, Group Product Manager
 
24.6. Cardiff University
24.6.1. Company Snapshot
24.6.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
 
24.7. Cerbios-Pharma
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
 
24.8. Eisai
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer
 
24.9. Lonza
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development
 
24.10. NBE-Therapeutics
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer
 
24.11. Oxford BioTherapeutics
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Christian Rohlff, Chief Executive Officer and Founder
 
24.12. Pierre Fabre
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Christian Bailly, Director of CDMO
 
24.13. Piramal Healthcare
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Mark Wright, Site Head, Grangemouth
 
24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Director, Business Development
 
24.15. Syndivia
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Sasha Koniev, Chief Executive Officer and Co-Founder
 
24.16. Anonymous, Director, Business Development, Leading CMO
24.17. Anonymous, Chief Executive Officer, Leading CMO

25. APPENDIX 1: TABULATED DATA
 
26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List  of Figures

Figure 3.1. Evolution of Anticancer Treatments
Figure 3.2. Cancer Treatment: Types of Surgeries
Figure 3.3. Cancer Treatment: Types of Radiation Therapies
Figure 3.4. Cancer Treatment: Types of Chemotherapies
Figure 3.5. Components of an ADC
Figure 3.6. Comparative Analysis of Pharmacokinetic Properties of ADCs: Dosing Regimen, Cmax and T1/2
Figure 4.1. ADC Therapeutics Clinical Pipeline: Distribution by Phase of Development
Figure 4.2. ADC Therapeutics Clinical Pipeline: Distribution by Indication
Figure 4.3. ADC Therapeutics Clinical Pipeline: Distribution by Line of Treatment
Figure 4.4. ADC Therapeutics Clinical Pipeline: Distribution by Dosing Regimen
Figure 4.5. ADC Therapeutics Clinical Pipeline: Distribution by Type of Therapy
Figure 4.6. ADC Therapeutics Clinical Pipeline: Distribution by Target Antigen
Figure 4.7. ADC Therapeutics Clinical Pipeline: Distribution by Antibody Origin
Figure 4.8. ADC Therapeutics Clinical Pipeline: Distribution by Antibody Isotype
Figure 4.9. ADC Therapeutics Clinical Pipeline: Distribution by Type of Linker
Figure 4.10. ADC Therapeutics Clinical Pipeline: Distribution by Type of Payload / Warhead
Figure 4.11. ADC Therapeutics Clinical Pipeline: Distribution by Key Technology Providers
Figure 4.12. ADC Therapeutics Preclinical Pipeline: Distribution by Phase of Development
Figure 4.13. ADC Therapeutics Preclinical Pipeline: Distribution by Indication
Figure 4.14. ADC Therapeutics Preclinical Pipeline: Distribution by Target Antigen
Figure 4.15. ADC Therapeutics Preclinical Pipeline: Distribution by Key Players
Figure 4.16. ADC Therapeutics Developer Landscape: Distribution by Year of Establishment
Figure 4.17. ADC Therapeutics Developer Landscape: Distribution by Size of Developer
Figure 4.18. ADC Therapeutics Developer Landscape: Distribution by Geographical Location
Figure 4.19. ADC Therapeutics Developer Landscape: Logo Landscape
Figure 5.1. AbbVie: Annual Revenues, 2014 – H1 2019 (USD Billion)
Figure 5.2. Rovalpituzumab Tesirine / ROVA-T: Registered Clinical Trials
Figure 5.3. Teliso-V / Telisotuzumab Vedotin / ABBV-399: Registered Clinical Trials
Figure 5.4. Astellas Pharma: Annual Revenues, 2014–Q1 2019 (JPY Billion)
Figure 5.5. Enfortumab Vedotin: Registered Clinical Trials
Figure 5.6. ASG16-M8F: Registered Clinical Trials
Figure 5.7. AstraZeneca: Annual Revenues, 2014– H1 2019 (USD Billion)
Figure 5.8. LUMOXITI™: Registered Clinical Trials
Figure 5.9. Daichi Sankyo: Annual Revenues, 2014–Q1 2019 (JPY Billion)
Figure 5.10. Trastuzumab Deruxtecan / DS-8201a / DS 8201: Registered Clinical Trials
Figure 5.11. ImmunoGen: Annual Revenues, 2014–Q1 2019 (USD Million)
Figure 5.12. IMGN853 / Mirvetuximab Soravtansine: Registered Clinical Trials
Figure 5.13. Immunomedics: Annual Revenues 2014-2018 (USD Million)
Figure 5.14. IMMU-130: Registered Clinical Trials
Figure 5.15. Pfizer: Annual Revenues, 2014–H1 2019 (USD Billion)
Figure 5.16. BESPONSA®: Registered Clinical Trials
Figure 5.17. MYLOTARG™: Registered Clinical Trials
Figure 5.18. Roche: Annual Revenues, 2014–H1 2019 (USD Billion)
Figure 5.19. KADCYLA®: Registered Clinical Trials
Figure 5.20. RG-7596: Registered Clinical Trials
Figure 5.21. Seattle Genetics: Annual Revenues, 2014-H1 2019 (USD Million)
Figure 5.22. ADCETRIS®: Registered Clinical Trials
Figure 5.23. SGN-LIV1A: Registered Clinical Trials
Figure 5.24. Synthon: Annual Revenues, 2014-2018 (USD Million)
Figure 5.25. SYD985 / Trastuzumab Duocarmazine: Registered Clinical Trials
Figure 5.26. Bayer Healthcare: Annual Revenues, 2014– H1 2019 (EUR Billion)
Figure 5.27. BAY 94-9343: Registered Clinical Trials
Figure 5.28. Biotest Pharmaceuticals: Revenue, 2014-H1 2019 (EUR Million)
Figure 5.29. BT-062: Registered Clinical Trials
Figure 6.1. Leukemia: Disease Classification
Figure 6.2. Leukemia: Global Epidemiological Distribution
Figure 6.3. Lymphoma: Global Epidemiological Distribution
Figure 6.4. Multiple Myeloma: Global Epidemiological Distribution
Figure 6.5. Lung Cancers: Disease Classification
Figure 6.6. Lung Cancer: Global Epidemiological Distribution
Figure 6.7. Breast Cancer: Global Epidemiological Distribution
Figure 6.8. Ovarian Cancer: Global Epidemiological Distribution
Figure 6.9. Bladder Cancer: Global Epidemiological Distribution
Figure 6.10. Colorectal Cancer: Global Epidemiological Distribution
Figure 6.11. Prostate Cancer: Global Epidemiological Distribution
Figure 6.12. Gastric Cancer: Global Epidemiological Distribution
Figure 7.1. KOL Analysis: Distribution by Type of Organization
Figure 7.2. KOL Analysis: Geographical Distribution of Principal Investigators
Figure 7.3. KOL Analysis: Dot-Plot of Principal Investigators
Figure 7.4. KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 7.5. KOL Analysis: Most Prominent Key Opinion Leaders
Figure 9.1. Partnerships and Collaborations: Cumulative Trend by Year, 2011-2019
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2015 and Post 2015
Figure 9.4. Most Active Players: Distribution by Number of Partnerships
Figure 9.5. Partnerships and Collaborations: Regional Distribution
Figure 9.6. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1. Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Developer, 2011-2019
Figure 10.2. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2011-2019
Figure 10.3. Funding and Investment Analysis: Cumulative Amount Invested by Year, 2011-2019 (USD Million)
Figure 10.4. Funding and Investment Analysis: Average Amount Invested per Year, 2011-2019 (USD Million)
Figure 10.5. Funding and Investment Analysis: High Value Deals, 2011-2019
Figure 10.6. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2011-2019
Figure 10.7. Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2011-2019 (USD Million)
Figure 10.8. Most Active Players: Distribution by Number of Funding Instances
Figure 10.9. Most Active Players: Distribution by Amount Invested
Figure 10.10. Funding and Investment Summary, 2011-2019 (USD Million)
Figure 11.1. Patent Analysis: Distribution by Type of Patent
Figure 11.2. Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2019
Figure 11.3. Patent Analysis: Distribution by Geographical Location
Figure 11.4. Patent Analysis: Distribution by CPC Symbol
Figure 11.5. Patent Analysis: Emerging Focus Areas
Figure 11.6. Patent Analysis: Distribution by Type of Applicant
Figure 11.7. Leading Industry Players: Distribution by Number of Patents
Figure 11.8. Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.9. Patent Analysis: Benchmarking by Patent Characteristics
Figure 11.10. Patent Analysis: Benchmarking by Number of International Patents
Figure 11.11. Patent Analysis: Distribution of Patents Age (2000-2019)
Figure 11.12. Patent Analysis: Distribution of Patents by Geography (2014-2019)
Figure 11.13. Patent Analysis: Valuation Analysis
Figure 12.1. Academic Grant Analysis: Distribution by Number of Grants Awarded
Figure 12.2. Academic Grant Analysis: Distribution by Type of Grant
Figure 12.3. Academic Grant Analysis: Year-Wise Distribution by Grant Amount (USD Million)
Figure 12.4. Academic Grant Analysis: Distribution by Focus Area
Figure 12.5. Academic Grant Analysis: Distribution by Support Period
Figure 12.6. Academic Grant Analysis: Year-Wise Distribution across Leading Grant Types
Figure 12.7. Academic Grant Analysis: Distribution by States in the US
Figure 12.8. Leading Recipient Organizations: Distribution by Number of Grants
Figure 12.9. Leading Recipient Organizations: Distribution by Amount Awarded
Figure 12.10. Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 12.11. Academic Grant Analysis: Distribution by Administering Institute Center
Figure 12.12. Academic Grant Analysis: Distribution by Funding Institute Center
Figure 12.13. Key Project Leaders: Distribution by Number of Grants
Figure 13.1. Successful Drug Launch Strategy: ROOTS Framework
Figure 13.2. Successful Drug Launch Strategy: Product Differentiation
Figure 13.3. Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 13.4. Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Developing ADCs
Figure 13.5. Approval of Drugs in Multiple Geographies: Historical Timeline
Figure 13.6. Approved ADC Therapeutics: Promotional Activities through Product Websites
Figure 14.1. Promotional / Marketing Strategy: Product Website Analysis
Figure 14.2. Promotional / Marketing Strategy: Patient Brochure and Unique Features
Figure 14.3. Promotional / Marketing Strategy: Informative Downloads
Figure 14.4. ADCETRIS® Website Analysis: Messages for Healthcare Professionals
Figure 14.5. ADCETRIS® Website Analysis: Messages for Patients
Figure 14.6. ADCETRIS® Website Analysis: Patient Support Program
Figure 14.7. KADCYLA® Website Analysis: Messages for Healthcare Professionals
Figure 14.8. KADCYLA® Website Analysis: Messages for Patients
Figure 14.9. KADCYLA® Website Analysis: Patient Support Program
Figure 14.10. MYLOTARG™ Website Analysis: Messages for Healthcare Professionals
Figure 14.11. MYLOTARG™ Website Analysis: Messages for Patients
Figure 14.12. MYLOTARG™ Website Analysis: Patient Assistance Services
Figure 14.13. MYLOTARG™ Website Analysis: Pfizer Oncology Together Program
Figure 14.14. BESPONSA® Website Analysis: Messages for Healthcare Professionals
Figure 14.15. BESPONSA® Website Analysis: Messages for Patients
Figure 14.16. BESPONSA® Website Analysis: Patient Assistance Services
Figure 14.17. BESPONSA® Website Analysis: Pfizer Oncology Together Program
Figure 14.18. LUMOXITI™ Website Analysis: Messages for Healthcare Professionals
Figure 14.19. LUMOXITI™ Website Analysis: Messages for Patients
Figure 14.20. LUMOXITI™ Website Analysis: Patient Support Program
Figure 14.21. POLIVY™ Website Analysis: Messages for Healthcare Professionals
Figure 14.22. POLIVY™ Website Analysis: Messages for Patients
Figure 14.23. POLIVY™ Website Analysis: Patient Support Program
Figure 15.1. ADCs Clinical Studies: Distribution by Type of Therapy
Figure 15.2. ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Figure 15.3. ADCs Combination Therapy Clinical Studies: Distribution by Current Trial Status
Figure 15.4. ADCs Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination
Figure 15.5. ADCs Combination Therapy Clinical Studies: Distribution by Indications and Type of Combination
Figure 16.1. ADC Platforms: Technological Evolution
Figure 16.2. ADC Conjugation Platforms: Technology Landscape
Figure 17.1. First in Human Dose Calculation: Dose Escalation using BSA Conversion
Figure 17.2. Relationship between Dose-Limiting Toxicities and ADC Warhead
Figure 17.3. Maximum Tolerated Dose (MTD: Relationship between Drug to Antibody Ratio and Highest Non-Severely Toxic Dose (HNSTD)
Figure 18.1. ADC Therapeutics: Relative Share of Individual Processes in the Cost of Production
Figure 18.2. ADC Therapeutics: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (Without Licensing Fees) (%)
Figure 18.3. ADC Therapeutics: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (With Licensing Fees) (%)
Figure 18.4. ADC Therapeutics: Pricing Model Based on Patient Segment
Figure 18.5. ADC Therapeutics: Pricing Model Based on Reimbursement Approvals
Figure 19.1. ADC Contract Manufacturers: Distribution by Services Offered
Figure 20.1. Advantages of Companion Diagnostics
Figure 20.2. Companion Diagnostics: Distribution by Type of Target
Figure 20.3. Companion Diagnostics: Distribution by Type of Indication
Figure 21.1. Overall ADC Therapeutics Market, 2019-2030 (USD Billion)
Figure 21.2. ADC Therapeutics Market: Distribution by Target Indication, 2019, 2025 and 2030 (USD Billion)
Figure 21.3. ADC Therapeutics Market): Distribution by Type of Linker, 2019, 2025 and 2030 (USD Billion)
Figure 21.4. ADC Therapeutics Market: Distribution by Type of Payload, 2019, 2025 and 2030 (USD Billion)
Figure 21.5. ADC Therapeutics Market: Distribution by Type of Target Antigen, 2019, 2025 and 2030 (USD Billion)
Figure 21.6. ADC Therapeutics Market: Distribution by Geographical Region, 2019, 2025 and 2030 (USD Billion)
Figure 21.7. ADC Therapeutics Market: Distribution by Technology Providers, 2019, 2025 and 2030 (USD Billion)
Figure 21.8. ADCETRIS® Sales Forecast, till 2030 (USD Million)
Figure 21.9. KADCYLA® Sales Forecast, till 2030 (USD Million)
Figure 21.10. MYLOTARG™ Sales Forecast, till 2030 (USD Million)
Figure 21.11. BESPONSA® Sales Forecast, till 2030 (USD Million)
Figure 21.12. LUMOXITI™ Sales Forecast, till 2030 (USD Million)
Figure 21.13. POLIVYTM Sales Forecast, till 2030 (USD Million)
Figure 21.14. ASG-22ME / Enfortumab Vedotin Sales Forecast, till 2030: Base Scenario (USD Million)
Figure 21.15. BAT8001 Sales Forecast, till 2030 (USD Million)
Figure 21.16. DS-8201a / DS 8201 / Trastuzumab Deruxtecan Sales Forecast, till 2030 (USD Million)
Figure 21.17. IMMU-132 / Sacituzumab Govitecan Sales Forecast, till 2030 (USD Million)
Figure 21.18. IMGN853 / Mirvetuximab Soravtansine Sales Forecast, till 2030 (USD Million)
Figure 21.19. lpituzumab Tesirine Sales Forecast, till 2030 (USD Million)Rova-T / Rova
Figure 21.20. SYD985 / Trastuzumab Duocarmazine Sales Forecast, till 2030 (USD Million)
Figure 21.21. ABBV-399 / Teliso-V / Telisotuzumab Vedotin Sales Forecast, till 2030 (USD Million)
Figure 21.22. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine Sales Forecast, till 2030 (USD Million)
Figure 21.23. ADCT-402 / Loncastuximab Tesirine Sales Forecast, till 2030 (USD Million)
Figure 21.24. AGS 16M8F / AGS 16C3F Sales Forecast, till 2030 (USD Million)
Figure 21.25. AVID100 Sales Forecast, till 2030 (USD Million)
Figure 21.26. BAY 94-9343 Sales Forecast, till 2030 (USD Million)
Figure 21.27. GSK 2857916 / Anti-BCMA ADC Sales Forecast, till 2030 (USD Million)
Figure 21.28. HuMax-TF-ADC / Tisotumab Vedotin Sales Forecast, till 2030 (USD Million)
Figure 21.29. IMGN529 / Debio 1562 / Naratuximab Emtansine Sales Forecast, till 2030 (USD Million)
Figure 21.30. IMMU-130 / Sacituzumab Govitecan Sales Forecast, till 2030 (USD Million)
Figure 21.31. RC48 Sales Forecast, till 2030 (USD Million)
Figure 21.32. SGN-LIV1A / Ladiratuzumab Vedotin Sales Forecast, till 2030 (USD Million)
Figure 22.1. ADC Therapeutics: SWOT Analysis
Figure 22.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 23.1. Overall ADC Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)

List of Tables

Table 3.1. List of Approved Monoclonal Antibody Therapies
Table 3.2. Commonly Used Cytotoxins for ADC Therapeutics
Table 3.3. Occupational Exposure Limit Bands, Safebridge Consultants
Table 3.4. Comparison of Pharmacokinetic Properties: ADCs, Small Molecules and Monoclonal Antibodies
Table 4.1. ADC Therapeutics: Clinical Pipeline
Table 4.2. ADC Therapeutics Clinical Pipeline: Components Specific Details
Table 4.3. ADC Therapeutics: Discontinued Drugs
Table 4.4. ADC Therapeutics: Preclinical Pipeline
Table 4.5. ADC Therapeutics: Developer Overview
Table 4.6. Novel Drug Conjugates
Table 5.1. AbbVie: Company Overview
Table 5.2. AbbVie ADC Therapeutics Pipeline
Table 5.3. Rova-T: Registered Clinical Trials
Table 5.4. Teliso-V: Registered Clinical Trials
Table 5.5. AbbVie: Future Outlook
Table 5.6. Astellas Pharma: Company Overview
Table 5.7. Astellas Pharma: ADC Therapeutics Pipeline
Table 5.8. ASG-22ME: Registered Clinical Trials
Table 5.9. ASG 16C3F: Registered Clinical Trials
Table 5.10. Astellas Pharma: Future Outlook
Table 5.11. AstraZeneca: Company Overview
Table 5.12. AstraZeneca: ADC Therapeutics Pipeline
Table 5.13. LUMOXITI™: Registered Clinical Trials
Table 5.14. AstraZeneca: Future Outlook
Table 5.15. Daichii Sankyo: Company Overview
Table 5.16. Daichii Sankyo: ADC Therapeutics Pipeline
Table 5.17. DS-8201a / DS 8201 / Trastuzumab Deruxtecan: Registered Clinical Trials
Table 5.18. Daichii Sankyo: Future Outlook
Table 5.19. ImmunoGen: Company Overview
Table 5.20. ImmunoGen: ADCs Pipeline
Table 5.21. IMGN853: Registered Clinical Trials
Table 5.22. IMGN529: Registered Clinical Trials
Table 5.23. ImmunoGen: Future Outlook
Table 5.24. Immunomedics: Company Overview
Table 5.25. Immunomedics: ADC Therapeutics Pipeline
Table 5.26. IMMU-130: Registered Clinical Trials
Table 5.27. Immunomedics: Future Outlook
Table 5.28. Pfizer: Company Overview
Table 5.29. Pfizer: ADCs Pipeline
Table 5.30. BESPONSA®: Registered Clinical Trials
Table 5.31. MYLOTARG™: Registered Clinical Trials
Table 5.32. Pfizer: Future Outlook
Table 5.33. Roche / Genentech: Company Overview
Table 5.34. Roche / Genentech: ADC Therapeutics Pipeline
Table 5.35. KADCYLA®: Registered Clinical Trials
Table 5.36. RG-7596: Registered Clinical Trials
Table 5.37. Roche / Genentech: Future Outlook
Table 5.38. Seattle Genetics: Company Overview
Table 5.39. Seattle Genetics: ADC Therapeutics Pipeline
Table 5.40. ADCETRIS®: Registered Clinical Trials
Table 5.41. SGN-CD19A: Registered Clinical Trials
Table 5.42. Seattle Genetics: Future Outlook
Table 5.43. Synthon: Company Overview
Table 5.44. Synthon: ADC Therapeutics Pipeline
Table 5.45. SYD985 / Trastuzumab Duocarmazine: Registered Clinical Trials
Table 5.46. SYD985 / Trastuzumab Duocarmazine: Registered Clinical Trials
Table 5.47. Synthon: Future Outlook
Table 5.48. Bayer Healthcare: Company Overview
Table 5.49. Bayer Healthcare: ADC Therapeutics Pipeline
Table 5.50. BAY 94-9343: Registered Clinical Trials
Table 5.51. Bayer Healthcare: Future Outlook
Table 5.52. Biotest Pharmaceuticals: Company Overview
Table 5.53. Biotest Pharmaceuticals: ADC Therapeutics Pipeline
Table 5.54. BT-062: Registered Clinical Trials
Table 5.55. Biotest Pharmaceuticals: Future Outlook
Table 6.1. Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 6.2. Leukemia: List of Marketed Targeted Therapeutics
Table 6.3. Lymphoma: List of Marketed Targeted Therapeutics
Table 6.4. ADC Therapeutics for Leukemia and Lymphoma
Table 6.5. Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 6.6. ADC Therapeutics for Multiple Myeloma
Table 6.7. Lung Cancer: List of Marketed Targeted Therapeutics
Table 6.8. ADC Therapeutics for Lung Cancer
Table 6.9. Breast Cancer: List of Marketed Targeted Therapeutics
Table 6.10. ADC Therapeutics for Breast Cancer
Table 6.11. Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 6.12. ADC Therapeutics for Ovarian Cancer
Table 6.13. Bladder Cancer: List of Marketed Targeted Therapeutics
Table 6.14. ADC Therapeutics for Bladder Cancer
Table 6.15. Colorectal Cancer: List of Marketed Targeted Therapeutics
Table 6.16. ADC Therapeutics for Colorectal Cancer
Table 6.17. Prostate Cancer: List of Marketed Targeted Therapeutics
Table 6.18. ADC Therapeutics for Prostate Cancer
Table 6.19. Gastric Cancer: List of Marketed Targeted Therapeutics
Table 6.20. ADC Therapeutics for Gastric Cancer
Table 7.1. KOL Analysis: List of Principal Investigators
Table 7.2. KOL Analysis: List of Universities and Hospitals
Table 7.3. KOL Analysis: Roots Analysis Proprietary Scoring System
Table 7.4. Profile: KOL A (Celgene)
Table 7.5. Profile: KOL B (Western Regional Medical Center)
Table 7.6. Profile: KOL C (MedStar Washington Hospital Center)
Table 7.7. Profile: KOL D (Cancer Institute and Hospital)
Table 7.8. Profile: KOL E (Comprehensive Cancer Centers of Nevada)
Table 7.9. Profile: KOL F (Hopital Tenon)
Table 7.10. Profile: KOL G (Cleveland Clinic)
Table 9.1. ADC Therapeutics: Partnerships and Collaborations, 2011-2019
Table 10.1. ADC Therapeutics: Funding and Investments, 2011-2019
Table 10.2. ADC Therapeutics: Summary of Investments
Table 11.1. Patent: CPC Symbol Definitions
Table 11.2. Patent: Most Popular CPC Symbols
Table 11.3. Patent: List of Top CPC Symbols
Table 11.4. ADC Therapeutics: Summary of Patent Benchmarking Analysis
Table 11.5. Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
Table 11.6. Leading Patents: Distribution by Relative Valuation
Table 12.1. ADC Therapeutics: List of Academic Grants, 2011-2019
Table 13.1. ADCETRIS®: Drug Overview
Table 13.2. KADCYLA®: Drug Overview
Table 13.3. MYLOTARG™: Drug Overview
Table 13.4. BESPONSA®: Drug Overview
Table 13.5. LUMOXITI™: Drug Overview
Table 13.6. POLIVY™: Drug Overview
Table 13.6. ADCETRIS®: List of Conferences Before Approval
Table 13.7. MYLOTARG™: List of Conferences Before Approval
Table 13.8. KADCYLA®: List of Conferences Before Approval
Table 13.9. BESPONSA®: List of Conferences Before Approval
Table 13.10. LUMOXITI™: List of Conferences Before Approval
Table 13.11. POLIVY™: List of Conferences Before Approval
Table 13.12. ADCETRIS®: List of Conferences Post Approval
Table 13.13. KADCYLA®: List of Conferences Post Approval
Table 13.13. Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 15.1. FDA Approved Combination Therapies in Oncology, 2001-2019
Table 15.2. ADCs Combination Therapy Clinical Studies: Key Indications
Table 16.1. Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 15.2. Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 16.3. Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 16.4. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 16.5. Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 16.6. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 16.7. Third Generation ADC Technologies: Cysteine Rebridging
Table 16.8. Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 17.1. ADCs Non-Clinical Studies: Safety Packages Required
Table 17.2. Single Dose Study of KADCYLA® in Cynomolgus Monkey
Table 17.3. ADCs: Dose Limiting Toxicities in Clinical Studies
Table 18.1. ADC Components: Information on Cost by Type of Linker
Table 18.2. ADC Component: Information on Cost by Type of Cytotoxin
Table 18.3. Price of Marketed ADCs
Table 18.4. Price of Marketed Targeted Drugs
Table 19.1. List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 19.2. List of HPAPI and Cytotoxic Drugs Manufacturing Service Providers
Table 19.3. Contract Manufacturers for ADCs: Geographical Distribution
Table 19.4. One Stop Shops for ADC Manufacturing: Information on Location of Manufacturing Facilities
Table 20.1. Companion Diagnostics: List of Available / Under Development Tests for ADCs
Table 21.1. ADC Therapeutics: Expected Launch Years
Table 21.2. ADCETRIS®: Target Patient Population
Table 21.3. KADCYLA®: Target Patient Population
Table 21.4. MYLOTARG™: Target Patient Population
Table 21.5. BESPONSA®: Target Patient Population
Table 21.6. LUMOXITI™: Target Patient Population
Table 21.7. POLIVYTM: Target Patient Population
Table 21.8. ASG-22ME / Enfortumab Vedotin: Target Patient Population
Table 21.9. BAT8001: Target Patient Population
Table 21.10. DS-8201a / DS 8201 / Trastuzumab Deruxtecan: Target Patient Population
Table 21.11. IMMU-132 / Sacituzumab Govitecan: Target Patient Population
Table 21.12. IMGN853 / Mirvetuximab Soravtansine: Target Patient Population
Table 21.13. lpituzumab Tesirine: Target Patient PopulationRova-T / Rova
Table 21.14. SYD985 / Trastuzumab Duocarmazine: Target Patient Population
Table 21.15. ABBV-399 / Teliso-V / Telisotuzumab Vedotin: Target Patient Population
Table 21.16. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine: Target Patient Population
Table 21.17. ADCT-402 / Loncastuximab Tesirine: Target Patient Population
Table 21.18. AGS 16M8F / AGS 16C3F: Target Patient Population
Table 21.19. AVID100: Target Patient Population
Table 21.20. BAY 94-9343: Target Patient Population
Table 21.21. GSK 2857916 / Anti-BCMA ADC: Target Patient Population
Table 21.22. HuMax-TF-ADC / Tisotumab Vedotin: Target Patient Population
Table 21.23. IMGN529 / Debio 1562 / Naratuximab Emtansine: Target Patient Population
Table 21.24. IMMU-130 / Sacituzumab Govitecan: Target Patient Population
Table 21.25. RC48: Target Patient Population
Table 21.26. SGN-LIV1A / Ladiratuzumab Vedotin: Target Patient Population
Table 25.1. ADC Therapeutics Clinical Pipeline: Distribution by Phase of Development
Table 25.2. ADC Therapeutics Clinical Pipeline: Distribution by Indication
Table 25.3. ADC Therapeutics Clinical Pipeline: Distribution by Line of Treatment
Table 25.4. ADC Therapeutics Clinical Pipeline: Distribution by Dosing Regimen
Table 25.5. ADC Therapeutics Clinical Pipeline: Distribution by Type of Therapy
Table 25.6. ADC Therapeutics Clinical Pipeline: Distribution by Target Antigen
Table 25.7. ADC Therapeutics Clinical Pipeline: Distribution by Antibody Origin
Table 25.8. ADC Therapeutics Clinical Pipeline: Distribution by Antibody Isotype
Table 25.9. ADC Therapeutics Clinical Pipeline: Distribution by Type of Linker
Table 25.10. ADC Therapeutics Clinical Pipeline: Distribution by Type of Payload / Warhead
Table 25.11. ADC Therapeutics Clinical Pipeline: Distribution by Key Technology Providers
Table 25.12. ADC Therapeutics Preclinical Pipeline: Distribution by Phase of Development
Table 25.13. ADC Therapeutics Preclinical Pipeline: Distribution by Indication
Table 25.14. ADC Therapeutics Preclinical Pipeline: Distribution by Target Antigen
Table 25.15. ADC Therapeutics Preclinical Pipeline: Distribution by Key Players
Table 25.16. ADC Therapeutics Developer Landscape: Distribution by Year of Establishment
Table 25.17. ADC Therapeutics Developer Landscape: Distribution by Size of Developer
Table 25.18. ADC Therapeutics Developer Landscape: Distribution by Geographical Location
Table 25.19. AbbVie: Annual Revenues, 2014 – H1 2019 (USD Billion)
Table 25.20. Rovalpituzumab Tesirine / ROVA-T: Registered Clinical Trials
Table 25.21. Teliso-V / Telisotuzumab Vedotin / ABBV-399: Registered Clinical Trials
Table 25.22. Astellas Pharma: Annual Revenues, 2014–Q1 2019 (JPY Billion)
Table 25.23. Enfortumab Vedotin: Registered Clinical Trials
Table 25.24. ASG16-M8F: Registered Clinical Trials
Table 25.25. AstraZeneca: Annual Revenues, 2014– H1 2019 (USD Billion)
Table 25.26. LUMOXITI™: Registered Clinical Trials
Table 25.27. Daichi Sankyo: Annual Revenues, 2014–Q1 2019 (JPY Billion)
Table 25.28. Trastuzumab Deruxtecan / DS-8201a / DS 8201: Registered Clinical Trials
Table 25.29. ImmunoGen: Annual Revenues, 2014–Q1 2019 (USD Million)
Table 25.30. IMGN853 / Mirvetuximab Soravtansine: Registered Clinical Trials
Table 25.31. Immunomedics: Annual Revenues 2014-2018 (USD Million)
Table 25.32. IMMU-130: Registered Clinical Trials
Table 25.33. Pfizer: Annual Revenues, 2014–H1 2019 (USD Billion)
Table 25.34. BESPONSA®: Registered Clinical Trials
Table 25.35. MYLOTARG™: Registered Clinical Trials
Table 25.36. Roche: Annual Revenues, 2014–H1 2019 (USD Billion)
Table 25.37. KADCYLA®: Registered Clinical Trials
Table 25.38. KADCYLA® Sales: 2014-H1 2019 (CHF Million)
Table 25.39. RG-7596: Registered Clinical Trials
Table 25.40. Seattle Genetics: Annual Revenues, 2014-H1 2019 (USD Million)
Table 25.41. ADCETRIS®: Registered Clinical Trials
Table 25.42. ADCETRIS® Sales: 2014- H1 2019 (USD Million)
Table 25.43. SGN-LIV1A: Registered Clinical Trials
Table 25.44. Synthon: Annual Revenues, 2014-2018 (USD Million)
Table 25.45. SYD985 / Trastuzumab Duocarmazine: Registered Clinical Trials
Table 25.46. Bayer Healthcare: Annual Revenues, 2014– H1 2019 (EUR Billion)
Table 25.47. BAY 94-9343: Registered Clinical Trials
Table 25.48. Biotest Pharmaceuticals: Revenue, 2014-H1 2019 (EUR Million)
Table 25.49. BT-062: Registered Clinical Trials
Table 25.50. Partnerships and Collaborations: Cumulative Trend by Year, 2011-2019
Table 25.51. Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.52. Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2015 and Post 2015
Table 25.53. Most Active Players: Distribution by Number of Partnerships
Table 25.54. Partnerships and Collaborations: Regional Distribution
Table 25.55. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 25.56. Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Developer, 2011-2019
Table 25.57. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2011-2019
Table 25.58. Funding and Investment Analysis: Cumulative Amount Invested by Year, 2011-2019 (USD Million)
Table 25.59. Funding and Investment Analysis: Average Amount Invested per Year, 2011-2019 (USD Million)
Table 25.60. Funding and Investment Analysis: High Value Deals, 2011-2019
Table 25.61. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2011-2019
Table 25.62. Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2011-2019 (USD Million)
Table 25.63. Most Active Players: Distribution by Number of Funding Instances
Table 25.64. Most Active Players: Distribution by Amount Invested
Table 25.65. Funding and Investment Summary, 2011-2019 (USD Million)
Table 25.66. Patent Analysis: Distribution by Type of Patent
Table 25.67. Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2019
Table 25.68. Patent Analysis: Distribution by Geographical Location
Table 25.69. Patent Analysis: Distribution by Type of Applicant
Table 25.70. Patent Analysis: Distribution of Patents Age (2000-2019)
Table 25.71. Patent Analysis: Distribution of Patents by Geography (2014-2019)
Table 25.72. Academic Grant Analysis: Distribution by Number of Grants Awarded
Table 25.73. Academic Grant Analysis: Distribution by Type of Grant
Table 25.74. Academic Grant Analysis: Year-Wise Distribution by Grant Amount (USD Million)
Table 25.75. Academic Grant Analysis: Distribution by Support Period
Table 25.76. Academic Grant Analysis: Year-Wise Distribution across Leading Grant Types
Table 25.77. Leading Recipient Organizations: Distribution by Number of Grants
Table 25.78. Leading Recipient Organizations: Distribution by Amount Awarded
Table 25.79. Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 25.80. Academic Grant Analysis: Distribution by Administering Institute Center
Table 25.81. Academic Grant Analysis: Distribution by Funding Institute Center
Table 25.82. Key Project Leaders: Distribution by Number of Grants
Table 25.83. ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Table 25.84. ADCs Combination Therapy Clinical Studies: Distribution by Current Trial Status
Table 25.85. ADCs Combination Therapy Clinical Studies: Distribution by Indications and Type of Combination
Table 25.86. ADC Therapeutics: Relative Share of Individual Processes in the Cost of Production
Table 25.87. ADC Therapeutics: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (Without Licensing Fees) (%)
Table 25.88. ADC Therapeutics: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (With Licensing Fees) (%)
Table 25.89. ADC Contract Manufacturers: Distribution by Services Offered
Table 25.90. Companion Diagnostics for ADCs: Distribution by Type of Target
Table 25.91. Companion Diagnostics for ADCs: Distribution by Type of Indication
Table 25.92. Overall ADC Therapeutics Market, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Billion)
Table 25.93. ADC Therapeutics Market: Distribution by Target Indication, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.94. ADC Therapeutics Market: Distribution by Type of Linker, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.95. ADC Therapeutics Market: Distribution by Type of Payload, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.96. ADC Therapeutics Market: Distribution by Type of Target Antigen, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.97. ADC Therapeutics Market: Distribution by Geographical Region, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.98. ADCETRIS® Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.99. KADCYLA® Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.100. MYLOTARG™ Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.101. BESPONSA® Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.102. LUMOXITI™ Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.103. POLIVYTM Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.104. ASG-22ME / Enfortumab Vedotin Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.105. BAT8001 Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.106. DS-8201a / DS 8201 / Trastuzumab Deruxtecan Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.107. IMMU-132 / Sacituzumab Govitecan Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.108. IMGN853 / Mirvetuximab Soravtansine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.109. lpituzumab Tesirine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.110. SYD985 / Trastuzumab Duocarmazine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.111. ABBV-399 / Teliso-V / Telisotuzumab Vedotin Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.112. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.113. ADCT-402 / Loncastuximab Tesirine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.114. AGS 16M8F / AGS 16C3F Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.115. AVID100 Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.116. BAY 94-9343 Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.117. GSK 2857916 / Anti-BCMA ADC Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.118. HuMax-TF-ADC / Tisotumab Vedotin Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.119. IMGN529 / Debio 1562 / Naratuximab Emtansine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.120. IMMU-130 / Sacituzumab Govitecan Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.121. RC48 Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.122. SGN-LIV1A / Ladiratuzumab Vedotin Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)

List of Companies

The following companies and organizations have been mentioned in the report.

  1. 3SBio
  2. 5AM Ventures
  3. Abbott
  4. AbbVie
  5. AbGenomics
  6. ABL Bio
  7. Abraxis BioScience
  8. Abzena
  9. ACES Pharma
  10. Actinium Pharmaceuticals
  11. Adagene
  12. ADC Bio
  13. ADC   Therapeutics
  14. Adimab
  15. Advanced Biotechnologies Venture Fund
  16. Advanced Proteome Therapeutics
  17. Advantage Capital
  18. Advent Venture Partners
  19. Aesica Pharmaceuticals
  20. Agensys
  21. Agilent Technologies
  22. Agios Pharmaceuticals
  23. Agno Pharma
  24. Ajinomoto Althea
  25. Alexion Pharmaceuticals
  26. Alger 
  27. Algeta 
  28. Alkermes
  29. Allos Therapeutics
  30. Allozyne
  31. Ally Bridge Group
  32. Almac
  33. Alphora Research
  34. Alta Partners
  35. Alteogen
  36. Amatsigroup
  37. Ambrx
  38. Amgen
  39. Amgen Ventures
  40. Amoy Diagnostics
  41. AMPAC Fine Chemicals
  42. AMRI
  43. Angiex
  44. Antikor Biopharma
  45. APO-T
  46. Apricot Capital
  47. Aptuit
  48. Aravis
  49. Arch Pharmalabs
  50. ArrowMark Partners
  51. Asana BioSciences
  52. Ash Stevens
  53. Astellas Pharma
  54. AstraZeneca
  55. Asymchem Laboratories
  56. Atlas Venture
  57. Atreca
  58. Auven Therapeutics
  59. Avalon Ventures
  60. Avanthera
  61. Avicenna Oncology
  62. Baxter BioPharma Solutions
  63. Bayer HealthCare
  64. BDC Capital
  65. BeiGene
  66. BerGenBio
  67. Beth Israel Deaconess Medical Center
  68. Bicycle Therapeutics
  69. BioAlta
  70. Biogen Idec
  71. BioGeneration Ventures
  72. BioGenex
  73. BioMed Valley Discoveries
  74. BioSynthesis Pharma
  75. Biotest
  76. Bio-Thera Solutions
  77. BioVectra
  78. BlinkBio
  79. Boehringer Ingelheim
  80. BOM Capital
  81. Bregua Corporation
  82. Bristol-Myers Squibb
  83. Bryllan
  84. BSP Pharmaceuticals 
  85. BZL Biologics
  86. Calculus Capital
  87. California Institute for Regenerative Medicine
  88. Cambrex
  89. Cambridge Innovation Capital
  90. Cambridge Major Laboratories
  91. Canaan
  92. Cancer Prevention and Research Institute of Texas  
  93. Cancer Research UK
  94. Capsugel
  95. CARBOGEN AMCIS
  96. Carb-X
  97. Casdin Capital
  98. Catalent
  99. Cedarburg Pharmaceuticals
  100. CEL Healthcare Fund
  101. Celgene
  102. Cellectar Biosciences
  103. Cellerant Therapeutics
  104. CellMosaic
  105. Celltrion
  106. Celon Laboratories
  107. Centre for the Commercialization of Antibodies and Biologics
  108. Centrose 
  109. Cerbios-Pharma 
  110. ChemCon
  111. ChemSun Pharmaceutical
  112. Children’s Hospital Los Angeles
  113. Chugai Pharmaceutical
  114. Cisbio
  115. Clovis Oncology
  116. Coldstream Laboratories
  117. Concortis Biotherapeutics
  118. CordenPharma
  119. Corixa
  120. Cormorant Asset Management
  121. Creative Biolabs
  122. Credit Suisse First Boston Next Fund
  123. Crescendo Biologics
  124. Crocker Ventures
  125. Crystal Pharma
  126. CSPC Pharmaceutical Group
  127. CTI Life Sciences Fund
  128. CureMeta
  129. Custom Pharma Services
  130. Cytogen
  131. CytomX Therapeutics
  132. Daiichi Sankyo
  133. Dalton Pharma Services
  134. Debiopharm
  135. Deerfield Management
  136. DKFZ German Cancer Research Center
  137. Dorizoe Lifesciences
  138. DOTTIKON EXCLUSIVE SYNTHESIS
  139. DSM Pharmaceuticals
  140. Dyax
  141. EirGen Pharma
  142. Eisai
  143. Elan Pharma
  144. Elasmogen
  145. Elder Pharmaceuticals
  146. Eleven Biotherapeutics
  147. Eli Lilly
  148. Elusys Therapeutics
  149. EMD Serono
  150. Esperance Pharmaceuticals
  151. Essex Bio-Technology
  152. ETH Zurich
  153. EUCODIS Bioscience
  154. Evonik Industries
  155. Excella 
  156. Exelixis
  157. Farmabios 
  158. Femtogenix Ink
  159. Ferring Pharmaceuticals
  160. Fidelity Investments
  161. FineTech Pharmaceutical
  162. Fonds de solidarité FTQ
  163. Forbius
  164. Formex
  165. Formosa Laboratories
  166. Fortis Therapeutics
  167. Fosun Pharma
  168. Foundation Medicine
  169. F-Prime Capital
  170. GamaMabs Pharma
  171. Genentech
  172. Genmab
  173. Gilead Sciences
  174. Global Bio
  175. Glycotope
  176. Glykos
  177. Goodwin Biotechnology
  178. GP-Pharm
  179. GSK
  180. GT Biopharma
  181. Halozyme Therapeutics
  182. Hangzhou DAC Biotech
  183. Harris Group
  184. Haupt Pharma
  185. HBM Healthcare Investments
  186. HealthCap
  187. Heidelberg Pharma
  188. Helsinn Advanced Synthesis
  189. Heraeus Deutschland
  190. Hercules Capital
  191. Hisun Pharmaceuticals
  192. HOPU Investments
  193. Human Genome Sciences
  194. Humanwell Healthcare Group
  195. Iconic Therapeutics
  196. ICROM
  197. Idifarma
  198. IDT Australia
  199. Igenica Biotherapeutics
  200. Iksuda Therapeutics
  201. ImClone Systems
  202. ImmunoBiochem 
  203. ImmunoGen
  204. Immunomedics
  205. Indena
  206. Innate   Pharma
  207. Innovate UK
  208. Intas Pharmaceuticals
  209. Invenra
  210. Invivoscribe
  211. IONTAS
  212. iProgen Biotech
  213. IRIX Pharmaceuticals
  214. Janssen Biotech
  215. Jazz Pharmaceuticals
  216. Jennison Associates
  217. Jiangsu Hengrui Medicine
  218. Johnson & Johnson
  219. Johnson Matthey (Pharma Services)
  220. Kairos Therapeutics
  221. Karyopharm Therapeutics
  222. Kite Pharma
  223. KLUS Pharma
  224. Kyongbo Pharmaceutical
  225. Kyowa Hakko Kirin
  226. Labochim 
  227. LegoChem Biosciences
  228. Leica Biosystems
  229. Levena Biopharma
  230. Ligand Pharmaceuticals
  231. Light Chain Bioscience
  232. Lilly Asia Ventures
  233. Lilly Ventures
  234. LinXis
  235. Longwood Fund
  236. Lonza
  237. Louisiana Fund
  238. Lumira Ventures
  239. MAB Discovery
  240. MabPlex
  241. MabSpace Biosciences
  242. MabVax Therapeutics
  243. MacroGenics
  244. Magenta Therapeutics
  245. Max Delbrück Center for Molecular Medicine
  246. MediaPharma
  247. Medichem
  248. MedImmune
  249. Meditope Biosciences
  250. Medivation
  251. Memorial Sloan Kettering Cancer Center
  252. Menarini
  253. Merck
  254. Metrics Contract Services
  255. Millennium Pharmaceuticals
  256. MilliporeSigma
  257. Minakem 
  258. Minomic
  259. Mitsubishi Tanabe Pharma
  260. MorphoSys
  261. Morphotek
  262. MS Ventures
  263. MuseChem
  264. NanoValent Pharmaceuticals
  265. Natco Pharma
  266. National Cancer Institute
  267. National Cancer  Institute
  268. NBE Therapeutics
  269. NerPharMa
  270. Nerviano Medical Sciences
  271. New Enterprise Associates
  272. Noonday Asset Management
  273. Nordic Nanovector
  274. Normon Laboratories
  275. Northeast Securities Prosperity Healthcare Fund
  276. Novartis
  277. Novasep
  278. Novo Holdings
  279. Olon 
  280. Omni Chem
  281. Oncolinx
  282. Oncomatryx Biopharma
  283. Onconova Therapeutics
  284. Onyx Pharmaceuticals
  285. OPKO Health
  286. Orano Med
  287. OrbiMed Advisors
  288. Organon Teknika
  289. Osage University Partners
  290. OsoBio
  291. Otsuka Pharmaceutical
  292. Oxford BioTherapeutics
  293. Oxford Finance
  294. Palatin Technologies
  295. Patheon
  296. Paul Scherrer Institute
  297. Penn Pharma
  298. Perceptive Advisors
  299. Pfanstiehl
  300. Pfizer
  301. Pharmaceutics International
  302. Pharmacyclics
  303. PharmaMar
  304. Pharmatek
  305. Philochem
  306. Philogen
  307. Pierre Fabre
  308. Piramal Pharma Solutions
  309. PolyTherics
  310. Poniard Pharmaceuticals  
  311. PPF Group
  312. PrasFarma
  313. ProBioGen
  314. Procos
  315. ProJect Pharmaceutics
  316. ProLynx
  317. ProQuest Investments
  318. Puma Biotechnology
  319. QIAGEN
  320. QS Pharma
  321. Quantum   Leap Investments 
  322. Rakuten Medical
  323. Ramot
  324. Recepta Biopharma
  325. Recipharm
  326. Redmile Group
  327. Regeneron Pharmaceuticals
  328. Regis Technologies
  329. RemeGen
  330. Research Corporation Technologies
  331. Rho Ventures
  332. Roche
  333. Rock Springs Capital
  334. Rottendorf Pharma
  335. Royalty Pharma
  336. Saltigo
  337. Samsung Medical Center
  338. Sandoz
  339. Sanofi
  340. Sanofi Genzyme
  341. Sarah Cannon Research Institute
  342. SBI Holdings
  343. ScinoPharm
  344. Scripps Research Institute
  345. Seattle Genetics
  346. Servier 
  347. Shanghai Fosun Pharmaceutical
  348. Shanghai Fudan-zhangjiang Bio-Pharmaceutical
  349. Shanghai Miracogen  
  350. Shanghai Pharma
  351. Shenogen Pharma
  352. Shire
  353. Siamab Therapeutics
  354. Siegfried
  355. Silicon Valley Bank
  356. Sinopharm Capital
  357. Skyline Ventures
  358. Sorrento Therapeutics
  359. SOTIO
  360. Spectrum Pharmaceuticals
  361. Spirogen
  362. SpringWorks Therapeutics
  363. SR One
  364. STA Pharmaceutical
  365. Starling Ventures
  366. Stason Pharmaceuticals
  367. Stemcentrx
  368. Sun Pharmaceutical Industries
  369. Sutro Biopharma
  370. SV Life Sciences
  371. Swedish Orphan Biovitrum
  372. Symphogen
  373. Synaffix
  374. Syndivia
  375. Syngene
  376. Syntagon
  377. Syntarga
  378. Synthon Biopharmaceuticals
  379. Synthorx
  380. Taiho Oncology
  381. TaiMed Biologics
  382. Takeda Oncology
  383. TBD-Biodiscovery
  384. Tekla Healthcare Investors
  385. Tekla Life Science Investors
  386. Teruisi Pharmaceutical
  387. TESARO
  388. Teva Pharmaceutical Industries
  389. The Column Group
  390. The Scripps Research Institute
  391. Themelios Ventures
  392. Theratechnologies
  393. Thermo Fisher Scientific
  394. Thiel Capital
  395. ThioLogics
  396. Third Rock Ventures
  397. Tolmar
  398. TopoTarget
  399. Tot Biopharm
  400. TPG-Axon Capital
  401. Triphase Accelerator 
  402. Triton Funds
  403. Tubulis Technologies
  404. UCB
  405. Ultragenyx Pharmaceutical
  406. Uman Pharma
  407. United Therapeutics
  408. University College  of London 
  409. University Medical Center Groningen
  410. University of California
  411. University of Freiburg
  412. University of Georgia
  413. University of Wisconsin Carbone Cancer Center
  414. University  of Copenhagen
  415. UPM Pharmaceuticals
  416. Uquifa
  417. Vaccinex
  418. Valeant Pharmaceuticals
  419. VelosBio
  420. Venrock Healthcare Capital Partners
  421. Ventures West
  422. Verastem Oncology
  423. Vertex Ventures
  424. Visterra
  425. VivaMab
  426. Vivo Capital
  427. VUAB Pharma
  428. Watson Pharmaceuticals
  429. Wellington Management Company
  430. Wild Ventures
  431. Wild  Family Office
  432. WS Investments
  433. WT Investment Advisors Fund
  434. WuXi Biologics
  435. WuXi PharmaTech
  436. Xintela
  437. Y Biologics
  438. York University
  439. Yuhan Corporation
  440. Zhejiang Medicine

Segmentation

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:

  • Type of Payload
    • MMAE 
    • DM4
    • Camptothecin
    • DM1
    • MMAF 
    • Others
  • Type of Linker
    • VC 
    • Sulfo-SPDB
    • SMCC 
    • VA
    • Hydrazone 
    • Others
  • Target Indication
    • Breast cancer
    • Lymphoma 
    • Leukemia 
    • Urothelial cancer
    • Lung cancer 
    • Ovarian cancer
    • Others
  • Target Antigen
    • CD30
    • HER2
    • CD22
    • CD33
    • Others 
  • Technology Providers
    • Seattle Genetics 
    • ImmunoGen 
    • StemCentRx 
    • Immunomedics 
    • Others
  • Key Geographical Regions 
    • North America
    • Europe
    • Asia Pacific

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com